Avantect Pancreatic Cancer Test
Pancreatic cancer is the third leading cause of cancer-related deaths worldwide, with high mortality due to late-stage diagnosis and the lack of specific blood-based biomarkers. The Avantect Pancreatic Cancer Test is a liquid biopsy assay that detects circulating tumor DNA (ctDNA) in blood samples, focusing on epigenetic alterations. This test specifically identifies the presence of 5-hydroxymethylcytosine (5hmC) modifications in methylated cytosine bases, which are associated with pancreatic tumorigenesis. By leveraging next-generation sequencing (NGS) technology, the Avantect test provides a non-invasive means of detecting pancreatic cancer at varying stages with high sensitivity and specificity.
The Avantect test has been validated in patients at a high risk for developing pancreatic cancer, including those aged 50 and older who are newly diagnosed with type 2 diabetes and those with a genetic predisposition and/or family history of pancreatic cancer. The test’s performance has an overall sensitivity of 66.7% and specificity of 96.9%.
- Aids in the early detection and diagnosis of pancreatic cancer
- Supports risk assessment for individuals predisposed to pancreatic malignancies
- Complements existing diagnostic tools, such as imaging and conventional tumor markers (e.g., CA19-9)
Positive result
Detection of abnormal 5hmC epigenetic signals suggests the presence of pancreatic malignancy.
Negative result
No detectable abnormal epigenetic signals, indicating a lower likelihood of pancreatic cancer. However, absence of detection does not completely rule out malignancy.
Not detected
Whole blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: Unacceptable
- Nat Commun. 2020;11(1):5270. [PMID: 33077732]
- Clin Gastroenterol Hepatol. 2023;21(7):1802-1809.e6. [PMID: 36967102]
- Sci Rep. 2022;12(1):16566. [PMID: 36195648]
- Cancer Res. 2021;81(21):5662-5672. [PMID: 34479674]
- Mol Oncol. 2021;15(9):2456-2467. [PMID: 34346758]